Kissei Pharmaceutical (4547) Q3 2025 earnings summary

Executive summary

• Net sales rose 13.5% year-over-year to ¥65,669 million for the nine months ended December 31, 2024, driven by strong pharmaceutical sales and increased technical fees.

• Operating profit increased 1.8% year-over-year to ¥4,238 million, while ordinary profit declined 13.1% to ¥5,298 million due to lower non-operating income.

• Profit attributable to owners of parent grew 6.0% year-over-year to ¥8,840 million, supported by extraordinary gains from investment securities.

• Comprehensive income turned negative at ¥(723) million, mainly due to a significant drop in valuation difference on available-for-sale securities.

Financial highlights

• Basic earnings per share increased to ¥201.40 from ¥182.87 year-over-year.

• Gross profit margin improved as cost of sales ratio decreased, despite higher R&D and SG&A expenses.

• Total assets decreased to ¥248,930 million from ¥260,929 million at the previous fiscal year-end.

• Net assets declined to ¥211,318 million, mainly due to lower valuation on securities and treasury share transactions.

Outlook and guidance

• Full-year net sales forecast is ¥86,500 million, up 14.4% year-over-year, with operating profit projected at ¥5,000 million and profit attributable to owners of parent at ¥11,700 million.

• Basic earnings per share for the full year is forecast at ¥268.21.

• Dividend forecast raised to ¥90.00 per share for the fiscal year ending March 31, 2025.